1. Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines 11: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN).J Pediatr2000;137:SI-S46.
2.
2. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995;311:1600-1602.
3.
3. Anonymous. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526-535.
4.
4. Anonymous. The Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health. National Heart, Lung, and Blood Institute. Division of Blood Diseases and Resource; 2002.
5.
5. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83-89.
6.
6. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol. 2002;9:101-106.
7.
7. Anonymous. Sickle Cell Disease: Screening, Diagnosis, Management, and Counseling in Newborns and Infants. Clinical practice guideline 6. Rockville, MD: ahcpr, phs, US Department of HHS; 1993.
8.
8. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28:220-226.
9.
9. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102:171-177.
10.
10. Adams RJ, Mc Kie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42:699-704.
11.
11. Adams RJ, Mc Kie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11.
12.
12. Adams RJ, Ohene-Frempong K, Wang W. Sickle cell and the brain. Hematology. 2001:31-46.
13.
13. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
14.
14. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 2000;106:367-376.
15.
15. Rodriguez-Cortes HM, Griener JC, et al. Plasma homocysteine levels and folate status in children with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21:219-223.
16.
16. Kennedy TS, Fung EB, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA. Red blood cell folate and serum vitamin B12 status in children with sickle cell disease. J Pediatr Hematol Oncol. 2001;23:165-169.
17.
17. Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr1986;109:579-585.
18.
18. Williams LL, Wilimas JA, Harris SC, Day SW, Dancy RM, Wang WC. Outpatient therapy with ceftriaxone and oral cefixime, for selected febrile children with sickle cell disease. J Pediatr Hematol Oncol. 1996;18:257-261.
19.
19. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11-16.
20.
20. Anonymous. Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. APS clinical practice guideline; no. 1. Glenview IL: American Pain Society (APS), 1999.
21.
21. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Eng I J Med. 1995;333:699-703.
22.
22. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999; 340:1021-1030.
23.
23. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea, in children and young adults with sickle cell disease. Blood. 2001;97:3628-3632.
24.
24. Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea. on growth in children with sickle cell anemia: results of the H-UG-KIDS Study.J Pediatr2002; 140:225-229.
25.
25. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855-1865.
26.
26. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995; 333:206-213.
27.
27. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol. 2001;38:14-22.
28.
28. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol. 2001;38:5-13.
29.
29. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol. 1991;28:213-219.
30.
30. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21:518-522.
31.
31. Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell disease; incidence, risk factors and complications-an international multicentre study. BJUInt. 2002;90:898-902.
32.
32. Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95:78-82.
